Company intelligence / Profile preview

NeuroSolutions

Coventry, West Midlands, United Kingdom

Ownership: Private
Employees: ~15
Development stage: Other

Overview

NeuroSolutions has advanced two proprietary compounds—NSL-043 for neuropathic pain (completed Phase I) and NSL-101 for dental pain (completed Phase II). The company provides extensive preclinical and proof-of-concept electrophysiology services, supporting over 100 pharmaceutical and biotech clients in drug discovery for neurological and psychiatric conditions.

Therapeutic areas: NeurologyEndocrinologyPsychiatryOther
Modalities: Small moleculePeptidesProtein
Industry: Biotech

Partnerships

Pacific Discovery ServicesKamelia Therapeutics

Beyond the preview

Go deeper on NeuroSolutions.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NeuroSolutions.

Explore the full profile